起搏器心房自动阈值管理功能的临床研究

Clinical study on automatic management of atrial pacing thresholds in EnPulse pacemaker

目的:通过对植入起搏器患者的随访,了解心房自动阈值管理功能的可靠性和安全性。方法:选择植入Medtronic Enpulse双腔起搏器的患者43例,于植入起搏器后的1、3、6个月分别程控随访,用人工测定法和自动测定法测定起搏器的心房输出阈值、感知和导线阻抗。结果:植入起搏器1、3、6个月后,随访时人工测定和自动测定的心房输出阈值分别为(0.60±0.26)V与(0.60±0.23)V、(0.55±0.19)V与(0.56±0.18)V、(0.58±0.20)V与(0.59±0.21)V,差异无统计学意义;且心房感知度和导线阻抗的人工测定与自动测定间无差异。在心房自动起搏阈值测定过程中未诱发任何心律失常。结论:起搏器的心房自动阈值管理功能的临床应用是可靠和安全的。

Objective To evaluate the effectiveness and safety of atrial capture management （ACM） of EnPulse pacemaker. Methods Forty-three patients with an indication for pacemaker were implanted with Medtronic EnPulse pacemaker. ACM and manually measured atrial pacing thresholds, sensory level, and lead impedance were performed at 1 month, 3 months, and 6 months follow up after implantation. Results There were no statistical significant differences in atrial pacing threshoIds[（0.60±0.26）V vs （0.60±0.23）V, （0.55±0.19）V vs （0.56±0.18）V, （0.58±0.20）V vs （0.59±0.21）V], sensory level, and lead impedance at 1 month, 3 months, and 6 months follow up after implantation tested by ACM and manual measures. No atrial aiThythmias were observed during ACM test. Conclusions ACM of EnPulse pacemaker is safe and reliable.